Phase 2 Study of Elraglusib (9-Ing-41), a Glycogen Synthase Kinase-3β Inhibitor, in Combination with Gemcitabine Plus Nab-Paclitaxel in Patients with Previously Untreated Metastatic Pancreatic Cancer-Reference-Cited by-同舟云学术

Phase 2 Study of Elraglusib (9-Ing-41), a Glycogen Synthase Kinase-3β Inhibitor, in Combination with Gemcitabine Plus Nab-Paclitaxel in Patients with Previously Untreated Metastatic Pancreatic Cancer

Published:2024 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Mahalingam Devalingam,Saeed Anwaar,Powell Steven F.,Huerta Marisol,Sahai Vaibhav,Coveler Andrew L.,Davis Elizabeth J.,Steeghs Neeltje,Mulcahy Mary,Raufi Alexander,Cavalcante Ludimila,Cervantes Andrés,Berlin Jordan,Weisskittel Taylor,Ugolkov Andrey,Mazar Andrew P.,Mikrut William,Smith Sheri,Giles Francis J.,Carneiro Benedito A.

Publisher

Elsevier BV

Reference52 articles.

1. Warewolf Therapeutics Anwaar Saeed: leadership role with Autem therapeutics, Exelixis, KAHR medical and Bristol-Myers Squibb; consulting or advisory board role with AstraZeneca;Epizyme Therapeutics;Xilio therapeutics, Taiho, Amgen, Autem therapeutics, KAHR medical, and Daiichi Sankyo; institutional research funding from AstraZeneca

2. Servier and Taiho; receipt of equipment and supplies from Beigene, Cornerstone (previously Rafael); and travel support from ASCO, Cholangiocarcinoma Foundation, Histosonics, Lynx Group/Amplity, NCCN Andrew L. Coveler: consultation or participation in advisory boards for Halozyme;F Steven;Transthera; consulting fees from Amplity (previously Lynx Group), AstraZeneca, Autem, Delcath Systems, Histosonics, Ipsen, Incyte, Rafael (previously Cornertsone)

3. Davis: no conflict of interest Neeltje Steeghs: consultation or participation in advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, Ellipses Pharma, GlaxoSmithKline, Incyte; institutional research funding from Abbvie;J Elizabeth;Actuate Therapeutics, Amgen, Anaveon, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, CellCentric, Cogent Biosciences, Cresecendo Biologics

4. Cancer statistics, 2024;R L Siegel;CA Cancer J Clin,2024